SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Shattuck Labs Reports Third-Quarter 2026 Results and Business Highlights

Shattuck Labs said it initiated the RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn’s disease; the supplied trial detail is truncated.

STTK

Related stories